The “Non-hormonal Therapies for Women’s Health Market by Target Indication, Type of Molecule, Purpose of Therapy, Mechanism of Action, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
“Non-hormonal Therapies for Women’s Health Market 2021-2030″ report features an extensive study of the current market landscape of non-hormonal therapies, primarily focusing on prescription drugs. The study also includes an elaborate discussion on the future potential of this evolving market.
One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with non-hormonal therapies, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030.
“To date, 21 non-hormonal therapies have been approved”.
In recent years, the development and introduction of non-hormonal alternatives have revolutionized women’s healthcare. Brisdelle was the first of such products, approved in 2013 for the management of hot flashes in menopausal women. To date, 21 non-hormonal therapies (recent examples include OriahnnT, PhexxiT and Esmya) have been approved. Further, several such non-hormonal product candidates are under evaluation across different stages of product development.
The inherent advantages of non-hormonal therapies, such as better safety profile, ability to maintain hormonal balance and relatively short treatment courses, over their hormonal counterparts have been demonstrated both in clinical trials and post product approval studies. As a result, such products are currently preferred over hormone-based therapies, and the non-hormonal therapy pipeline is expected to continue to steadily expand over the coming years.
“Several stakeholders entering into strategic collaborations to support the ongoing product development and commercialization initiatives of such product“.
It is worth highlighting that significant partnership activity has been observed in this market, with several stakeholders entering into strategic collaborations to support the ongoing product development and commercialization initiatives of such products. In the foreseen future, promising results from the ongoing clinical research initiatives are likely to bring in more investments to support product development activity in this upcoming market segment. Therefore, we are led to anticipate significant growth in this domain in the coming years.
Key Questions Answered
- Who are the leading industry players engaged in the development of non-hormonal therapies?
- How many non-hormonal therapy candidates form the current development pipeline? Which key women’s health related disease indications are targeted by such products?
- Which commercialization strategies are most commonly adopted by non-hormonal therapy developers, across different stages of product development?
- Which partnership models are commonly adopted by stakeholders engaged in this domain?
- What are the key value drivers of the merger and acquisition activity in the non-hormonal therapies industry?
- Who are the key stakeholders that have actively made investments in the non-hormonal therapies domain?
- How is the current and future market opportunity likely to be distributed across key market segments?